| The molecular classification of multiple myeloma F Zhan, Y Huang, S Colla, JP Stewart, I Hanamura, S Gupta, J Epstein, ... Blood 108 (6), 2020-2028, 2006 | 1202 | 2006 |
| A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 JD Shaughnessy Jr, F Zhan, BE Burington, Y Huang, S Colla, I Hanamura, ... Blood 109 (6), 2276-2284, 2007 | 1049 | 2007 |
| Thalidomide and hematopoietic-cell transplantation for multiple myeloma B Barlogie, G Tricot, E Anaissie, J Shaughnessy, E Rasmussen, ... New England Journal of Medicine 354 (10), 1021-1030, 2006 | 874 | 2006 |
| Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells F Zhan, J Hardin, B Kordsmeier, K Bumm, M Zheng, E Tian, R Sanderson, ... Blood, The Journal of the American Society of Hematology 99 (5), 1745-1757, 2002 | 800 | 2002 |
| CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma ED Hsi, R Steinle, B Balasa, S Szmania, A Draksharapu, BP Shum, ... Clinical Cancer Research 14 (9), 2775-2784, 2008 | 605 | 2008 |
| Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related … I Hanamura, JP Stewart, Y Huang, F Zhan, M Santra, JR Sawyer, ... Blood 108 (5), 1724-1732, 2006 | 552 | 2006 |
| F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma TB Bartel, J Haessler, TLY Brown, JD Shaughnessy Jr, F van Rhee, ... Blood, The Journal of the American Society of Hematology 114 (10), 2068-2076, 2009 | 536 | 2009 |
| Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications R Walker, B Barlogie, J Haessler, G Tricot, E Anaissie, JD Shaughnessy, ... Journal of Clinical Oncology 25 (9), 1121-1128, 2007 | 475 | 2007 |
| International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease DC Fajgenbaum, TS Uldrick, A Bagg, D Frank, D Wu, G Srkalovic, ... Blood, The Journal of the American Society of Hematology 129 (12), 1646-1657, 2017 | 439 | 2017 |
| Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse F van Rhee, F Lin, JO Cullis, A Spencer, NC Cross, A Chase, ... | 430 | 1994 |
| Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial F Van Rhee, RS Wong, N Munshi, JF Rossi, XY Ke, A Fosså, D Simpson, ... The lancet oncology 15 (9), 966-974, 2014 | 410 | 2014 |
| Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis F Zhan, B Barlogie, V Arzoumanian, Y Huang, DR Williams, K Hollmig, ... Blood 109 (4), 1692-1700, 2007 | 401 | 2007 |
| A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma JA Zonder, AF Mohrbacher, S Singhal, F Van Rhee, WI Bensinger, H Ding, ... Blood, The Journal of the American Society of Hematology 120 (3), 552-559, 2012 | 391 | 2012 |
| Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents SZ Usmani, C Heuck, A Mitchell, J Szymonifka, B Nair, A Hoering, ... haematologica 97 (11), 1761, 2012 | 389 | 2012 |
| Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia F Dazzi, RM Szydlo, C Craddock, NCP Cross, J Kaeda, A Chase, ... Blood, The Journal of the American Society of Hematology 95 (1), 67-71, 2000 | 388 | 2000 |
| Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 B Barlogie, E Anaissie, F Van Rhee, J Haessler, K Hollmig, ... British journal of haematology 138 (2), 176-185, 2007 | 354 | 2007 |
| HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy DC Fajgenbaum, F van Rhee, CS Nabel Blood, The Journal of the American Society of Hematology 123 (19), 2924-2933, 2014 | 338 | 2014 |
| Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing L Rasche, SS Chavan, OW Stephens, PH Patel, R Tytarenko, C Ashby, ... Nature communications 8 (1), 268, 2017 | 322 | 2017 |
| Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities B Barlogie, M Pineda-Roman, F Van Rhee, J Haessler, E Anaissie, ... Blood, The Journal of the American Society of Hematology 112 (8), 3115-3121, 2008 | 291 | 2008 |
| A phase I, open-label study of siltuximab, an anti–IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease R Kurzrock, PM Voorhees, C Casper, RR Furman, L Fayad, S Lonial, ... Clinical cancer research 19 (13), 3659-3670, 2013 | 290 | 2013 |
